Advertisement

Search Results

Advertisement



Your search for Charlotte Bath matches 10 pages

Showing 1 - 10


colorectal cancer
hepatobiliary cancer
lung cancer
lymphoma

Increased Cancer Mortality Rate Among Recipients of Solid-Organ Transplants

Solid-organ transplant recipients have a higher rate of cancer mortality than what is expected in the general population, according to a Canadian study by Acuna et al published in JAMA Oncology. Cancer mortality among transplant recipients was significantly elevated compared with data for the...

lung cancer

‘Substantial Number’ of Patients Requiring Palliative Radiotherapy for Stage IV NSCLC Are Overtreated

An analysis of data from 46,803 patients with stage IV non–small cell lung cancer (NSCLC) who received palliative chest radiation therapy found that 49% received radiotherapy for longer than 15 fractions and 28% received more than 25 fractions. This treatment pattern “is inconsistent...

lung cancer

Adding Bevacizumab to Treatment of Patients With NSCLC May Lead to More Toxicity but Less Risk for Hospitalization

A study among patients with advanced non–small cell lung cancer (NSCLC) treated with carboplatin-paclitaxel or carboplatin-paclitaxel-bevacizumab (Avastin) found that those receiving the bevacizumab combination were more likely to experience a toxicity event but were less likely to be...

lung cancer
palliative care

Identifying Processes That Lead to Discontinuation of Chemotherapy for Patients With NSCLC at End of Life

According to a recent study by Perl et al published in the Journal of Oncology Practice, the administration of chemotherapy near death is recognized by patients, their families, and oncologists as “aggressive and poor-quality care.” Despite this, rates of end-of-life chemotherapy have...

issues in oncology
lung cancer

EGFR L858R Mutation in Circulating Free DNA From Blood Samples of Patients With Non–Small Cell Lung Cancer Shown to Be Negative Prognostic Marker

Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown...

lung cancer

Prior Cancer Does Not Affect Outcomes Among Patients With Advanced Lung Cancer

Analysis of data from 102,929 patients with stage IV lung cancer found that “prior cancer does not convey an adverse effect on clinical outcomes, regardless of prior cancer stage, type, or timing.” Based on these findings, investigators from the Harold C. Simmons Cancer Center,...

lung cancer
pancreatic cancer
issues in oncology

Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...

gynecologic cancers
colorectal cancer
head and neck cancer
kidney cancer
lung cancer
issues in oncology
bladder cancer
issues in oncology

14 Million Major Medical Conditions Attributable to Cigarette Smoking

At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...

lung cancer

FDG-PET Is Less Specific in Diagnosing Lung Cancer in Areas With Endemic Infectious Lung Disease

Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An...

lung cancer

ASCO 2014: Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer

Patients with stage IV non–small cell lung cancer (NSCLC) who relapsed after initial platinum-based therapy experienced extended overall survival with a combination of the antiangiogenic agent ramucirumab (Cyramza) and standard chemotherapy with docetaxel, compared to patients receiving...

Advertisement

Advertisement



Advertisement